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reemissions and exacerbations, until the end 
of life. Typical patient suffers from signifi-
cant comorbidities which arise from bron-
chial obstruction. These include progressive 
right-sided heart failure and cardiomyopathy 
which cause enormous medical spending 
on severe disease forms [4]. This was often 
main selection bias in other similar studies 
– how to be sure that incurred cost in parti-
cular patient could be COPD attributed and 
not to associated conditions? From our point 
of view, frankly it isn’t always clear whether 
these associated conditions precede or fol-
low COPD, thus we didn’t include cardio-
INTRODUCTION
Chronic obstructive pulmonary disease 
(COPD) is severely disabling and irreversi-
ble condition with lasting impact on quali-
ty of life and working ability of an indivi-
dual. Its huge impact on the health budgets 
worldwide puts it among five most expensi-
ve chronic disorders [1]. Few data are avai-
lable about COPD costs in lower and middle 
income world regions [2]. It is known that 
lifestyle, tobacco consumption and profes-
sional risk exposure play great role in COPD 
pathogenesis [3]. Once diagnosed, COPD 
shall last, through unpredictable cycles of 
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ABSTRACT
OBJECTIVE: Comparison of COPD financial burden and underlying factors, between Eastern upper middle income and a 
Western European high income, healthcare settings.
METHODS: The patient sample was 433 in Belgium and 322 in Serbia, age ≥ 40, with spirometry and clinically confirmed 
COPD diagnosis. Belgian trial followed patients prospectively during 2006, using structured survey of clinicians in charge. 
Serbian trial conducted in 2008, retrieved data from clinical invoice database. Time horizon was one year and perspec-
tive of third party payers was taken into account for both studies. Clinical outcomes of interest were disease exacerbation, 
hospital admission and death. Economic inputs referred to COPD-attributable medical services consumption value during 
observed period of time.  
RESULTS: Average annual cost was 1,812.84 € for the Serbian patients and 1,738.13 €/year for the Belgian patients (not 
including the value of laboratory diagnostics or imaging techniques). Severity grade and duration of hospital admissions 
significantly directly correlated with overall cost in both populations. Pattern of diagnostic procedures requested and ATC 
classes of drug consumed to treat COPD remains similar and comparable in both countries. GDP per capita ratio in respec-
tive years (10.4: 37.4), exhibits the paradox of patient being much less affordable to treat in a less developed society.
CONCLUSIONS: Burden of COPD in Europe is huge and, due to contemporary life style expected to grow further. We 
compared cost of illness structures between two societies with different macroeconomic past in healthcare financing and 
management. According to our findings, direct medical costs were driven by exacerbations and hospital admissions. Sig-
nificantly cheaper human labor caused higher relative relevance of drug acquisition expenses in the East and higher portion 
of hospital admission costs in the West. More in-depth research of indirect COPD attributable costs (e.g. lost productivity, 
absenteeism, premature death etc) will be needed in future. It implies serious health policy necessities to provide acces-
sibility of care.
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vascular diseases related consumption in the 
overall picture.
Systematic review findings show that pre-
valence above the age of 40 could be even 
as high as 9% in Western European countri-
es [5]. Different COPD financial burden of 
disease estimates in high income countries, 
show that average patient spends 900-1,500 
€/year from societal perspective [1]. We can 
easily calculate enormous economic and he-
alth care resources consumption imposed on 
a health budget by this single chronic illness. 
It should be mentioned that, in most countri-
es, it has been classified among top ten cau-
ses of mortality [6,7].
This paper presents one of the first health 
economic efforts worldwide of comparing 
two different microeconomic settings in he-
alth care. Aim of the trial was to measure and 
explain possible differences in cost structure 
between two countries with different health 
care systems representing two main econo-
mic models inherited from recent past: Serbia 
and Belgium. In these two national health sy-
stems within countries with comparable size 
and demographic structure (Caucasian popu-
lation, 10.4 vs. 7.4 million inhabitants, low 
fertility rate, average age 41+) we can obser-
ve very different economic milieu. Serbia, 
as a middle income country, had estimated 
annual GDP per capita 3.6 times lower than 
Belgian ones in 2009 (10.400$ and 37.400$, 
respectively) [8]. According to official WHO 
statistics, total health expenditure expressed 
as percentage of gross domestic product was 
8% in Serbia and 9.6% in Belgium [9]. As 
a transitional eastern European economy, in 
the recent past it had only mandatory gene-
ral health insurance for employed and their 
families and provided almost equal access 
to available health care (mostly state owned 
sector) to all citizens irrespective to their in-
come level. However in the past decade ex-
panded voluntary health insurance package 
was introduced and also major changes were 
made in sense of shifting outpatient and less 
expensive inpatient services towards priva-
tely owned health care sector. Health econo-
mic assessment based on decision making is 
actually still taking roots with local policy 
makers in governmental sector, although it is 
very important for countries with lower he-
alth budget. It still has to prepare its way as a 
useful tool for assignment of resources which 
are significantly poorer then OECD average 
[10].
On the other side Belgian national health 
care system provides several types of health 
insurance. Financing of public medical needs 
comes from both one large national and se-
veral smaller private insurance funds. Access 
to health care is guaranteed to the almost all 
layers of population (regardless of income le-
vel). Health economic evaluation reports as a 
way for informed decision making have been 
conducted since the early 90ties. Health sy-
stem itself has been ranked 21st in the world 
by overall quality of care by WHO estimates 
in 2000 [9,11,12].
OBJECTIVE
Our comparison of COPD burden estimates 
was conducted with the two aims:
1. Evaluate the annual national costs of 
COPD in Serbia and Belgium and struc-
ture of services and goods needed to deal 
with them;
2. Try to define differences in cost matrix 
and in total cost due to existing differen-
ces in societal milieu and health care sy-
stem.
METHODS
The Authors used available data acquired 
through prospective (Belgium) and retro-
spective (Serbia) research approach.
Serbian cost of illness analysis was conducted 
as observational, retrospective, bottom up, 
third party payer’s perspective, case study. 
It used clinical centre invoice registry for 
2008 with invoices (imposed to state Health 
Insurance Fund) for given services and go-
ods consumed by patients, including drugs. 
These economic data originated from ward 
clerks regular updating of electronic payment 
invoices given to the patient at the discharge 
from hospital. Medical and economical data 
related to patients with clinically and spiro-
metrically confirmed COPD (ICD J40-J47) 
were retrieved. Sample size was 322 patients 
of both sexes and aged above 40. Clinical 
data relied on patient’s medical records taken 
from The Pulmonary Diseases Clinic archi-
ve, Clinical Center Kragujevac, in Kraguje-
vac, Serbia, the main one in the region with 
approximately 600,000 inhabitants. All at-
tending physicians were specialist pulmono-
logists. Diagnostic criteria and grading were 
used in line with Global Initiative for Chronic 
Obstructive Lung Disease recommendations. 
They commonly also had positive history of 
productive chronic cough and auscultatory 
signs of irreversible bronchial obstruction 
[13]. Clinical outcomes of interest were: 
exacerbation, hospitalization and death. The 
utilization of resources imposed by patient 
who deceased during the course of the study 
was added to the overall costs because they 
contribute to the costs attributable to COPD 
in a given year. There were 15 such cases. 
Although some exacerbations could be suc-
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cessfully treated out of hospital, majority of 
others required necessary ICU and pulmono-
logy department admission. These were ex-
pected to be major drivers of increased health 
services utilization (previous experiences of 
other authors) and were carefully noticed. 
Recording of utilized health services was li-
mited to inpatient diagnostic procedures and 
treatments and specialist physician’s outpa-
tient services at the clinic. Number of hospi-
tal admissions, their duration and number of 
outpatient consultations were also evidenced 
in unit amounts (days and absolute numbers). 
Costs were separated into following classes: 
hospital admission charges (including Inten-
sive Care Unit and inpatient consultations), 
laboratory diagnostic procedures, imaging 
diagnostic procedures, interventions, drugs 
and outpatient chest physician consultations. 
Non-pharmacological therapeutic interven-
tions ranging from surgery, physiotherapy 
to complementary medicine treatments were 
suited into a single file together. The practice 
of including physician’s consultations in the 
charge of daily inpatient care is today com-
mon to many hospital management systems. 
Neither primary care nor home occurring di-
rect medical expenses were considered.
Belgian cost of illness analysis was an in-
depth, prospective, observational, bottom 
up, third party payer’s perspective, case cli-
nical study. 41 general practitioners and 21 
pulmonologists participated in the survey. 
The physicians have completed one survey 
per each patient providing all the necessary 
data. The study included 433 patients with 
COPD (195 patients from GPs, 238 from 
pulmonologists), aged above 40 in 2006, 
with detailed evidence on their medical tre-
atment needs and consumption. There was 
an equal distribution of patients among the 
GPs/pulmonologists. Basic method to acqui-
re these data was structured questionnaire 
delivered to physicians in charge, in order to 
report all direct medical costs associated with 
this diagnosis in 2006. The physician sample 
was representative in terms of regional and 
urban versus non-urban distribution. Patients 
were not assigned due to their place of resi-
dence but were rather scattered all around the 
country. Clinical outcomes of interest and 
diagnostic inclusion/exclusion criteria remai-
ned the same as in Serbian twin study. Drug 
acquisition costs in both samples were rela-
ted only to the medicines necessary to treat 
COPD or associated clinical conditions (an-
ticholinergics, beta2 agonist, inhaled cortico-
steroid, antibiotics, methylxantine, etc). Cost 
calculation in both countries was based on 
respective official pricelist of national health 
insurance funds.
Chosen time horizon believed to be enough 
long to cover most outcomes of interest, in 
both of them, was one year. Authors needed 
to make economic outlook truly comparable 
due to two year gap between studies. Di-
scount rates used for this purpose were de-
rived from “Health Index” and found to be 
around 104. Third party payer’s or health 
insurance fund’s perspective was adopted for 
this research for few reasons. In general, ma-
jor part of COPD-related expenses occur due 
to inpatient treatment of exacerbations there-
fore direct medical costs would probably be 
sufficiently representative for the entire cost 
of illness. Except that, societal perspective 
would require an in-depth estimate of indi-
rect costs attributable to lost productivity: 
absenteeism, impaired working ability, early 
retirement, premature mortality which would 
have been out of the scope of this paper and 
the available budget. See Table I for metho-
dological comparison.
Health care costs are given in a parallel man-
ner, sorted for both samples. Serbian part of 
calculation was done in national currency 
(Central Serbian Dinar, CSD) converted to 
Euro relying on an official exchange rate of 
National Bank of Serbia for 2008 (1€ = 78.9 
CSD). Market values of health care goods 
and services provided was in both countries 
overtaken from an official pricelist given by 
National Health Insurance Funds.
Graphical analysis of data was conducted by 
means of Microsoft Office Excel 2010 and 
with Systat Software SigmaPlot commercial 
package version 11.2 s for which The Medi-
cal Faculty University of Kragujevac, Serbia 
has purchased institutional license number 
E08A6986 - C790C936.
Study limitations
Methodological weaknesses of this compa-
rative economic evaluation stands for time 
gap 2006 for Belgian and 2008 for Serbian 
data but we could justify it by the fact that 
discount rates were applied and respective 
inflation rates were taken into account. Ano-
Methodology Serbian data Belgian data
Study design Observational, 
retrospective, bottom‑up, 
case study
Observational, prospective, 
bottom‑up, case study
Perspective Third party payers Third party payers
Source of data Clinical files, invoice registry GPs and specialists survey
Sample size 322 433
Inclusion 
criteria
COPD spirometry and 
clinically confirmed
COPD spirometry and/or 
clinically confirmed
Table I. Short overview of both study designs
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It is easily demonstrated that other, so called 
“prosperity diseases” like diabetes mellitus 
2, essential hypertension, cardiomyopathy, 
arrhythmias etc. arising from sedentary life 
styles, are present in majority of these pa-
tients. The most are proven to be related to 
tobacco consumption, are incurable life time 
disorders and significantly contribute to pa-
tient’s medical needs [5].
Next part of measurements deals with num-
ber of hospital admissions due to COPD 
exacerbations at the population level. Ave-
rage number of hospitalizations per person 
was 1.5 times vs. 0.24 and its duration 14 vs. 
2.83 days (Serbia vs. Belgium). An average 
cost of exacerbation treated was € 322.5 vs. 
€ 1,336.82, and average number of outpatient 
visits was 2.9 for the Eastern European and 
3.9 for Western European population. Please 
see Table III and Figure 1 for more details.
Direct medical cost (€) Serbia Belgium
Laboratory diagnostics 120.37 Unavailable data
Imaging techniques 171.79 Unavailable data
Drug acquisition costs
(inpatient expenditure)
980.22 799.7
Hospital admission* 493.02 744.1
Outpatient consultations 47.44 196.2
Cost/patient/year without 
diagnostic services included
1,520.68 1,738.13
Total cost/patient/year 
(average +/‑ standard error)
1,812.84 1,738.13
Table III. Measured costs of consumed medical goods and services in a given 
year for both samples of general COPD population (€/patient/year)
* Specialist’s consultations, Intensive Care Unit admissions included
Figure 1. Stratified column chart presenting cost matrix comparison between 
countries, created using comparable set of respective data, acquired through 
similar methodological framework
both countries) in an academic twin clinical 
trial justifies the efforts. An additional issue 
was the fact that Serbian patients originate 
from central region and single large specia-
list clinic while Belgian ones were dispersed 
across the country.
Our idea is quite an unexploited one in the 
field of health economics, to compare to sub-
stantially different health care markets not 
only in terms of their level of development 
but quite a lot in sense of health policy stra-
tegies and financing approach too. Most of 
costs subdomains were carefully collected 
and split to be attributable particularly to the 
COPD morbidity (drugs, examinations and 
treatments outsourcing from comorbidities 
were excluded) in both samples. Those do-
mains are truly comparable and refer to the 
equivalent values in two societies. We belie-
ve that uneasy task we decided for, will meet 
the needs of both policy makers and health 
practitioners making real-time clinical deci-
sions.
Statistical analysis
Statistical analysis of data was conducted by 
means of IBM SPSS commercial software 
package version 18, for which The Faculty 
Medical Sciences University of Kragujevac, 
Serbia has purchased institutional license 
number, SPSS ID: 729157.
By means of Spearman’s rho nonparametric 
correlation test we probed significance of se-
veral hypothetical causal relationships:
 - Summary duration of exacerbations 
(days) towards amount of costs incurred 
per particular patient;
 - Severity of disease (according to GOLD 
classification stage) towards amount 
of costs incurred per particular patient. 
Within 95% confidence interval and p 
value ≤ 0.05 we found out that both sup-
posed relationships could be considered 
significant in both populations.
Number of observations was 319 for Serbian 
and 433 for Belgian side. According to Kol-
mogorov Smirnof test results (p < 0.05, p = 
0.000), we considered data to be nonparame-
tric. We used Spearman’s rho nonparametric 
correlation test (significant correlation was 
for P value < 0.05) to test the impact on to-
tal direct medical costs of different variables 
(male sex, age, GOLD severity stage, number 
of hospitalizations, duration of hospitaliza-
tions, pack years, smoker).
RESULTS
Severity stage structures of population obser-
ved is given in the Table II because it is con-
sidered to have a decisive impact on overall 
cost of disease.
Serbia Belgium
Severity stage N. % Severity stage N. %
I 68 21.3 I 62 (14.3)
II 54 16.9 II 190 43.9
III 123 38.6 III 140 32.3
IV 74 23.2 IV 41 9.5
All stage 319 100 All stage 433 100
Table II. Severity grade structure, according to GOLD classification of COPD
ther issue is quite a different way of obtaining 
data implying highly likely different quality 
and reliability of the same ones. Methodo-
logical differences could be regarded as the 
source of bias. Nevertheless an ambitious 
task of comparing such large samples (752 in 
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See Table IV for the linear regression analysis 
results of different variables impact on total 
direct medical costs.
DISCUSSION
At first, we were thinking of what could be 
the optimal approach when faced to such re-
search question. In basic, most appropriate to 
counting real world expenses would be retro-
spective study design. This is so, due to lack 
of researcher’s subjectivity and no need for 
blinding, for we explore things that happened 
in the past. Protocol is also not interfering 
into physician’s practices, which commonly 
much differ from good clinical practice gui-
delines [12]. For an example in one large 
sample study, inhaled corticosteroids where 
prescribed twice as much as first line recom-
mended ipratropium [14]. Disadvantage of 
Dependent 
variable‑covariate
Total cost
Serbia Belgium
Coefficients (95% CI) P value Coefficients (95% CI) P value
Male sex 0.077 (‑0.036:0.193) 0.170 ‑0.070 (‑0.159:0.034) 0.148
Age ‑0.77 (‑0.192:0.035) 0.170 0.108 (0.013:0.200) 0.025
GOLD severity stage 0.458 (0.355:0.556) 0.000 0.478 (0.406:0.545) 0.000
Number of hospitalizations 0.437 (0.349:0.524) 0.000 0.262 (0.179:0.341) 0.000
Duration of hospitalizations 0.422 (0.319:0.510) 0.000 0.254 (0.167:0.339) 0.000
Pack Years Data not available 0.007 (‑0.163:0.179) 0.934
Smoker Data not available ‑0.118 (‑0.223:‑0.015) 0.014
Table IV. Linear regression analysis results of different variables impact on total direct medical costs (Spearman’s rho nonparametric 
correlation test used)
Figure 2. Scatter plots of COPD medical care costs in patients compared between countries (Serbian sample exhibits more central 
tendency but several extreme values, Belgian ones more overall heterogeneity inside sample)
It is easily demonstrated that other, so called 
“prosperity diseases” like diabetes mellitus 
2, essential hypertension, cardiomyopathy, 
arrhythmias etc. arising from sedentary life 
styles, are present in majority of these pa-
tients. The most are proven to be related to 
tobacco consumption, are incurable life time 
disorders and significantly contribute to pa-
tient’s medical needs [5].
Next part of measurements deals with num-
ber of hospital admissions due to COPD 
exacerbations at the population level. Ave-
rage number of hospitalizations per person 
was 1.5 times vs. 0.24 and its duration 14 vs. 
2.83 days (Serbia vs. Belgium). An average 
cost of exacerbation treated was € 322.5 vs. 
€ 1,336.82, and average number of outpatient 
visits was 2.9 for the Eastern European and 
3.9 for Western European population. Please 
see Table III and Figure 1 for more details.
Direct medical cost (€) Serbia Belgium
Laboratory diagnostics 120.37 Unavailable data
Imaging techniques 171.79 Unavailable data
Drug acquisition costs
(inpatient expenditure)
980.22 799.7
Hospital admission* 493.02 744.1
Outpatient consultations 47.44 196.2
Cost/patient/year without 
diagnostic services included
1,520.68 1,738.13
Total cost/patient/year 
(average +/‑ standard error)
1,812.84 1,738.13
Table III. Measured costs of consumed medical goods and services in a given 
year for both samples of general COPD population (€/patient/year)
* Specialist’s consultations, Intensive Care Unit admissions included
Figure 1. Stratified column chart presenting cost matrix comparison between 
countries, created using comparable set of respective data, acquired through 
similar methodological framework
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steroid + antibiotic + methylxantine. Some 
of these patients will even undergo surgical 
removal of hyperinflated lung tissue. We 
observed that patients in later stages of natu-
ral disease progression would probably cost 
even 2-3 times more than average [19].
Services provided by means of outpatient 
visits were usually GP’s and chest physician 
consultations mostly, basic lab and spiromet-
ry controls. They fall in range of 2-3% of all 
costs. This is in accordance with different fin-
dings elsewhere [14,16, 20-28].
CONCLUSIONS
Both epidemiological and financial burden 
of chronic obstructive pulmonary disease on 
contemporary health budgets is enormously 
heavy. With 9% prevalence after the age of 
40, massive professional risk exposure and 
tobacco smoking lifestyle, traditionally favo-
red in Balkans region and Turkey, it is even 
expected to rise further. We decided to com-
pare two different health care settings faced 
with the same problem. They had very dif-
ferent economic background and health care 
sector financing and management in recent 
past – state controlled as opposed to free mar-
ket model.
One can notice that an average GDP per capi-
ta (Purchase Power Parity basis) income was 
3.6 stronger in the West, but disease (com-
pared as average COPD cost per patient per 
year) is likely to be only some 12.5% less 
expensive in the East. According to this fact 
we have the paradox of this illness curren-
tly being more affordable to combat with, 
in high-income societies. Human labor wa-
ges rose continually in eastern European and 
Balkans countries during past two decades. 
Anyway they remain at pretty lower level 
than in the West. The truly comparable part 
of COPD expenses mentioned between our 
samples, are drug acquisition costs. Among 
drugs we may see that, when of DDD units 
(defined daily doses) consumption is consi-
dered, patterns of prescription do not differ 
significantly. Also unit prices provided by 
national insurance funds could be treated si-
milar.
From overall picture provided by these two 
observational studies we can conclude seve-
ral facts:
 - Hospital admissions due to exacerbations 
are major driver of costs incurred;
 - Drugs consumption has similar structure 
in both societies;
 - Services relying on human labor (unli-
ke lab analysis. an example of physician 
consultations) are still significantly more 
expensive in western European condi-
tions.
this half of our design was of course lack of 
some important data e.g. professional toxic 
exposure, tobacco smoking habit details.
Our second half, prospective clinical case stu-
dy design, while limited by certain inclusion 
criteria, did not define schedule of consul-
tations and interventions in its protocol and 
thereafter provided plenty of highly reliable 
data. Here we do miss diagnostic resources 
consumption but have an in-depth data regar-
ding other sorts of costs and patient’s medical 
background.
We could see that diagnostics account for 
16.12% of all costs in eastern European sam-
ple (Figure 1). This is in line with findings 
of Coleva et al. in Italian population on 2007 
[15]. Treatment costs of up to 54% in Serbian 
and 46% in Belgian sample (diagnostics was 
excluded for comparability) declines from 
the dominant assumption that drug acquisi-
tion costs should be expected at 16% level 
[16]. It is probably due to the fact that bet-
ter funded multicenter COPD cost of illness 
trials often included indirect expenses too in 
the overall picture. Relative number of ho-
spital admission days due to sickness exacer-
bation, calculated per person, is significantly 
smaller in Belgian population and overall ad-
mission is much more seldom than in Serbian 
setting. At the same time, price of an average 
hospitalization is even four times higher. This 
could be explained by higher level of patient 
compliance to treatment or regularly sche-
duled consultations which succeeded to dia-
gnose it earlier in stage easier to be treated. 
Severity grade spectrum shows that eastern 
European sample was dominated by more 
severe disease forms more than western one. 
This fact exhibits impact to total costs if we 
observe level of dissipation shown in scatter 
plots (Figure 2).
More extreme values in Serbian patients are 
accompanied by other findings showing that 
tobacco consumption and nicotine depen-
dence is deeply rooted in Balkans countries 
and related to COPD prevalence [17]. When 
we consider hypothesis that severity grade 
influences costs, it’s inevitable to mention 
earlier efforts in regard to this matter of Jans-
son et al. They approved that there is certain 
predictability [18]. More gravely ill patients 
are likely to often suffer from bronchial ob-
struction, productive cough and breathing 
difficulties and be hospitalized because of 
these symptoms. They will also be probably 
more expensive to society than others. It will 
be necessary for them to conduct extensive 
lab monitoring e.g. partial blood pressure of 
gasses. Many of them will receive simulta-
neously several drug treatments e.g. anticho-
linergic + beta2 agonist + inhaled cortico-
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wer income societies. Health care budgets are 
evidently more threatened by chronic disea-
ses in an economic environment with scarcer 
resources.
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Serbian part of this research, together with 
one Romanian and few Polish studies publi-
shed in native languages was probably one 
of few pioneering cost of illness determina-
tion efforts related to prosperity diseases in 
Eastern Europe [29-36]. This could be con-
ducted from the huge lack of knowledge on 
costs of most important prosperity diseases in 
this part of the world. We assume that further 
in-depth evidence on indirect costs of COPD, 
would still be needed in future, especially in 
order to reveal true picture in middle and lo-
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